Home' Australian Pharmacist : Australian Pharmacist November 2015 Contents Australian Pharmacist November 2015 I ©Pharmaceutical Society of Australia Ltd. 77
SuperStream makes super
Small business owners with 19 or
fewer employees need to start paying
super contributions and sending
member information electronically
through SuperStream, according to the
Australian Tax Office.
The new, streamlined process, which
came into effect on 1 July, provides
a consistent and simplified way for
employers to make super contributions
on behalf of their employees.
Under SuperStream, those responsible
for paying super guarantee for
pharmacy and cosmetics businesses will
be able to pay super to multiple super
funds in one transaction -- saving time
More than 250,000 employers
nationwide, including around
150,000 small employers, have already
made the switch.
Kylie Dixon from Ainslie Pharmacy in the
ACT has already adopted SuperStream
and found the amount of time needed
to pay super for the pharmacy's
employees has reduced significantly.
'I can make all super contributions to all
employees, through the one fund's site.
I do mine through REST. I can pay all my
REST employees and everyone else too;
MLC, Guild, plus all the others. I've been
using SuperStream for 10 or 12 months.
SuperStream has reduced my processing
time from three hours every month to
around 20 minutes,' she said
Philip Hind, the Australian Taxation
Office's National Program Manager, Data
Standards & E-Commerce (SuperStream),
said the ATO was assisting the pharmacy
and cosmetics industry, sending
important information to registered
business owners via email, text message,
contacting relevant industry
associations and held a dedicated
SuperStream webinar on 13 October.
The ATO step-by-step checklist to help
employers prepare can be found at:
PSA seeks biosimilar
A consensus Australian document on
terminology and definitions relating
to biological medicines, including
biosimilar medicines, should be
developed as a priority to promote
accurate and common understanding of
this subject the Pharmaceutical Society
of Australia believes.
In its biosimilar medicines position
statement, PSA says patient safety
is a prime concern of the pharmacy
profession and risk assessment
in relation to biosimilars includes
assessment of safety and efficacy by
the Therapeutic Goods Administration,
consideration by the Pharmaceutical
Benefits Advisory Committee, and
clinical assessment by the prescriber.
National President of the PSA,
Joe Demarte, said pharmacists currently
followed substitution principles which
respected the choice of prescribers
and patients, in accordance with
PSA's Professional Practice Standards,
and Guidelines for Pharmacists on PBS
'In consideration of possible
long-term impacts of biological
medicines generally, but biosimilar
medicines in particular, PSA believes
a holistic, nationally-coordinated
and outcomes-focussed approach is
essential for a strong pharmacovigilance
program,' Mr Demarte said.
PSA has suggested a stakeholder group
be established to determine appropriate
parameters which may include an
extension of routine pharmacovigilance
Slow growth in Hep B
The value of the global Hepatitis B
Virus (HBV) therapeutics market will
increase modestly over the next six
years, from almost $3 billion in 2014
to $3.5 billion by 2021 -- a Compound
Annual Growth Rate (CAGR) of 2.3% --
according to business intelligence
provider GBI Research.
The company's report, Hepatitis B
Therapeutics in Major Developed Markets
to 2021 -- Increasing Number of Migrants
from High-Prevalence Regions to Drive
Market Growth, claims the rise will occur
across the eight major markets of the US,
Canada, the UK, France, Germany, Italy,
Spain and Japan, and will be primarily
driven by increasing immigration from
medium and high-prevalence countries.
GBI Research Analyst Priyatham
Salimadugu said: 'The US, which has one
of the largest shares of the HBV treatment
market, sees considerable migration from
high-prevalence countries, such as the
Philippines, China, and Vietnam.
'While immigration will enlarge the
patient pool, HBV treatment market
expansion will be restricted by
prophylactic vaccination in the US and
much of Europe.'
However, the analyst adds that the
increasing use of the premium therapies
tenofovir and entecavir will help to drive
the market during the forecast period.
Despite this, the global late-stage
pipeline is weak due to the lack of
first-in-class and innovative products in
late-stage clinical development.
Links Archive Australian Pharmacist October 2015 Australian Pharmacist December 2015 Navigation Previous Page Next Page